UF startup and UF Innovate | Sid Martin Biotech alum Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced that the Department of Defense (DOD), through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA), has awarded the company with three biomanufacturing contracts with a combined value of more than $16 million.
“We are pleased to be working with DTRA on these important programs,” said Peter H. Khoury, president and CEO at Ology Bioservices. “The diverse biomanufacturing technologies employed in these three programs clearly demonstrate the capabilities of our team at Ology Bioservices and the functionality of the Advanced Development and Manufacturing Facility.”Learn more about Ology Bioservices Wins Three Department of Defense Awards Totaling More Than $16 Million.
Related news:Department of Defense Awards Ology Bioservices Contract to Advance Anti-Botulinum Neurotoxin Monoclonal Antibodies. Ology Bioservices to Adapt Veroplex Cell Platform for Rapid Response to Viral Threats for Department of Defense. Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Million Department of Defense Grant. Ology Bioservices, Vanderbilt University Medical Center to Develop, Manufacture Monoclonal Antibody for Treatment, Prevention of Infection With COVID-19 Virus for Department of Defense.